(Q38231991)

31 August 2017

title

Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma (English)

1 reference

31 August 2017

Kaitlin N Highsmith

1

1 reference

31 August 2017

Sheree E Chen

series ordinal

2

1 reference

31 August 2017

Sandy Horowitz

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 July 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

34

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

927-940

1 reference

31 August 2017

1 reference

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

A monoclonal gammopathy precedes multiple myeloma in most patients

21 January 2018

1 reference

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival

21 January 2018

1 reference

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma

21 January 2018

1 reference

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

21 January 2018

1 reference

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

21 January 2018

1 reference

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

21 January 2018

1 reference

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

21 January 2018

1 reference

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

21 January 2018

1 reference

Novel immunomodulatory compounds in multiple myeloma

21 January 2018

1 reference

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.

21 January 2018

1 reference

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

21 January 2018

1 reference

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

21 January 2018

1 reference

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

21 January 2018

1 reference

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

21 January 2018

1 reference

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

Pulmonary toxicity associated with the use of lenalidomide: case report of late-onset acute respiratory distress syndrome and literature review.

21 January 2018

1 reference

Acute lung toxicity related to pomalidomide

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1463

1 reference

31 August 2017

1 reference